The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/190998

Please be advised that this information was generated on 2020-03-13 and may be subject to change.
From Diabetes Care to Diabetes Cure—The Integration of Systems Biology, eHealth, and Behavioral Change

Ben van Ommen1*, Suzan Wopereis1, Pepijn van Empelen2, Hilde M. van Keulen2, Wilma Otten2, Marise Kasteleyn3, Johanna J. W. Molema4, Iris M. de Hoogh1, Niels H. Chavannes3, Mattijs E. Numans3, Andrea W. M. Evers5,6 and Hanno Pijl7

1 Netherlands Organization for Applied Scientific Research (TNO), Department of Microbiology and Systems Biology, Leiden, Netherlands, 2 Netherlands Organization for Applied Scientific Research (TNO), Department of Child Health, Leiden, Netherlands, 3 Leiden University Medical Center (LUMC), Department of Public Health and Primary Care, Leiden, Netherlands, 4 Netherlands Organization for Applied Scientific Research (TNO), Department of Work Health Technology, Leiden, Netherlands, 5 Department of Health, Medical and Neuropsychology, Leiden University Medical Centre, Leiden University, Leiden, Netherlands, 6 Department of Psychiatry, Leiden University Medical Centre, Leiden University, Leiden, Netherlands, 7 Leiden University Medical Center (LUMC), Department of Internal Medicine, Leiden, Netherlands

OPEN ACCESS

INTRODUCTION

Current health care in the area of lifestyle-related diseases does not focus on reversal of the cause of the disease, but rather on controlling disease corollaries by manipulating biochemical pathways (gluconeogenesis by metformin, hepatic cholesterol synthesis by statins, insulin secretion by sulfonylureas, fatty acid housekeeping by PPAR agonists, etc.). A large repertoire of tools, technologies, and medicinal treatments has been developed for this purpose. Chronic
disease care and (cardiovascular) risk management have been vastly improved thanks to these possibilities. However, we are running into the situation that disease care soon becomes too costly, with a number of stakeholders that either financially profit from the status quo or find the effort to change it too complicated. Also, unfavourable drivers in our healthcare economy maintain this situation, as only reductionist solutions can be patented. In the context of our current healthcare system, citizens become patients in the literal sense of the word: patiently undergoing treatments instead of playing an active role in their own health care. In the end, this is an inefficient approach for treatment of the so-called “lifestyle related diseases,” including metabolic syndrome, obesity, type 2 diabetes, and cardiovascular disease (1, 2). Moreover, we now know that our lifestyle partakes in the pathogenesis of many other diseases [e.g., inflammatory diseases like rheumatoid arthritis, COPD, gastroesophageal reflux disease, osteoarthritis, neurological diseases like Alzheimer and multiple sclerosis, and specific cancers (3–5)]. Over the past 10 years, an integrated view on health and health care was developed, embracing health as a system (i.e., including systems biology concepts and technologies), the development of disease from health as a continuum and exploiting these assets toward “P4-medicine” (Predictive, Personalized, Preventive, and Participatory) (6, 7). The personalized aspect emerged from the possibilities to quantify the causal mechanisms involved disease predisposition (genetics) and development (environment), while the participatory aspect related both to the health and medical data ownership (8) and the need for patient citizens to take optimal control of all aspects of their own health, spanning all biopsychosocial aspects (9, 10). In this article, we will focus and elaborate on type 2 diabetes as an exemplary prototype of a lifestyle-related disease, but very similar concepts and approaches are valid for many other diseases. The theoretical framework of P4 medicine and P4 health is now solid, but yet difficult to translate into daily practice of health care for a number of reasons, mostly related to conflicting stakeholder interest and cost of implementation. Some examples are emerging, but mostly in an experimental and costly setting (7, 11). Type 2 diabetes is also interesting as the disease is not only part of a continuum from health to comorbidities and preventable but also to a large extend reversible and curable with relatively simple means, once P4 or P6 health is implemented, as will be demonstrated below.

Type 2 diabetes is a "genotype–environment interaction disease," where the diabetic phenotype is expressed as a result of accumulated environmental pressures (wrong diet, too little physical exercise, disrupted sleep, and too much stress) in concert with genes that render individuals susceptible to the disease. Over the past 50 years or so, our environment has changed in a way that has increased the burden of all four components mentioned. Reversal and cure of type 2 diabetes thus needs to focus on (1) biological reversal (i.e., using lifestyle as medicine), (2) on coping with the environmental pressures (i.e., behavioral change), and (3) on reduction of the environmental pressures (i.e., socioeconomic changes). All of these three areas will be discussed. Thus, the healthcare approach toward lifestyle-related diseases needs to change. Huge health and economic profits can be achieved if everyone would adopt an “optimal” lifestyle. This article presents abundant scientific evidence that major reductions in obesity, type 2 diabetes, and cardiovascular disease can be achieved through lifestyle interventions (12, 13). In fact, the (economic) benefits of a lifestyle-based therapy for type 2 diabetes have been demonstrated in a 10-year study (14). Yet, the introduction of a new healthcare system for lifestyle-related diseases (both therapy and prevention) does not materialize for a number of reasons, as discussed in this article. One of the major motives for not using lifestyle measures in clinical practice is the difficulty to sustain the changes. In the short term, or in a rigidly imposed, lifestyle change can be achieved, but in long-term daily life changes easily fade away due to the lack of support and the many counteracting stimuli from environmental pressure. Other major reasons for failure of lifestyle as medicine are the lack of economic benefits in the context of the current healthcare model; and the failure to use a systems approach instead of reductionist changes (15). Thus, theory and practice differ and we face a multifactorial challenge, requiring the removal of economic, social, psychological, and biological barriers.

A reorientation of health research and care is needed, starting with (re)defining health and its underlying mechanisms, realizing that integrated participatory and personalized health optimization strategies are needed, redesigning the methods to quantify health toward the development of a new generation of health biomarkers (16), lifestyle interventions (17), supporting tools and economical values, all aiming at self-empowerment, as listed below.

1. Refocusing on flexibility as core characteristic of physiology, allowing reversibility of disease.
2. Diagnosis has to quantify much more than the medical condition. A 360° diagnosis is needed that determines all relevant biological, sociological, psychological, and contextual conditions of the patient and the trajectory toward disease need to be identified and quantified, to empower the individual to achieve a sustainable and perceivable lifestyle change.
3. Interventions will need to span all relevant bio-socio-psycho-economic factors and thus change from reductionist to systemic and from generic to fine-tuning toward personal goals.
4. Motivational tools are required in the form of personal coaching as well as ICT support.
5. Health literacy needs to be improved as part of personal health empowerment.
6. Personal health data handling needs to completely refocus by empowering the citizen/patient valorize their health data for personal health and research.
7. Together, this needs to lay the foundations of both a new approach in lifestyle-related health science and health economy.

Each of these aspects is further detailed in the paragraphs below.
THE BIOLOGY

Type 2 Diabetes Can Be Cured

Although the definition of “cure,” “reversal,” or “remission” of type 2 diabetes has been a matter of debate (18), various lines of evidence have demonstrated that T2D is a reversible disease. Bariatric surgery generally leads to remission of type 2 diabetes in obese people, although with large heterogeneity among patients (19, 20). The mechanisms are not completely understood, but beta-cell function recovery seems to be limited (21). Lifestyle intervention can bring about significant improvements in risk factors for cardiovascular disease in T2D patients, as indicated by a meta-analysis of studies (22). Most of these studies evaluated relatively “mild” monodisciplinary interventions (i.e., only dietary advice, or education, physical activity, general advice, etc.). These are discussed in detail below. Intensive lifestyle intervention studies have shown very promising results. Reversal of type 2 diabetes by omitting sugars and starches from the diet may reduce or even abolish the need for glucose control medication. Yet, from a mechanistic point of view, cure would only be achieved if low-grade inflammation and oxidative damage are reversed, insulin sensitivity has been restored in all relevant organs, and insulin production by the beta-cell is sufficient. Organ insulin sensitivity can be restored by various lifestyle interventions, primarily through weight loss and reduction of intra-organ adipose deposits. This is discussed in the succeeding paragraphs. Improvement of beta-cell function by lifestyle intervention was described by Taylor (23). Recent mechanistic evidence documenting diet-induced beta-cell regeneration adds to the story (24). Finally, various “atypical” forms of diabetes, mostly with a monogenetic origin, cannot be cured by lifestyle change alone (although lifestyle change has a major impact on metabolic control even in those patients) due to their underlying cause (25). In conclusion, lifestyle change can restore the pathobiology of “typical” T2D to normal in patients who still have sufficient insulin secretory capacity.

Systems Flexibility As Characteristic of Metabolic Health and Disease

The metabolic state of patients with type 2 diabetes is routinely quantified in a symptomatic manner, i.e., by the fasting plasma glucose concentration (the acute symptom) and HbA1c (the accumulated symptom). Yet, these are the consequences of a complex network of interactions between food intake and fuel metabolism, involving multiple organs and biochemical pathways. For optimal metabolic health, each of these processes needs to function optimally. We argue that effective treatment of type 2 diabetes requires appropriate quantification of the multiple processes leading to disease itself, its progression, and its cure. In this context, it is important to note that type 2 diabetes is not a uniform disease. There are probably many subtypes with their own pathophysiology, born out of specific gene–lifestyle interactions (26). If this is the case, there is no optimal “one size fits all” treatment of type 2 diabetes. Each disease variant most likely requires its own therapeutic approach.

Most of the metabolic processes that go awry in type 2 diabetes have to function in a continuously changing environment (diet, infections, stress, temperature, exercise, etc.) where they strive to maintain internal homeostasis by adapting to these changes, usually in an hour–day timescale. Under chronic external stress (month–year timescale: high calorie diets, chronic inflammation), two major adaptation processes occur. On the one hand, the molecular physiology that regulates the acute stress response reactions accelerates to maintain homeostasis of the important parameters, possibly at the cost of other parameters. During caloric excess, plasma glucose, triglycerides, and inflammatory markers are initially maintained at normal levels, as a result of elevated concentrations of insulin, glucagon, and other regulatory mechanisms (27). However, prolonged caloric excess invokes adaptive processes like storage of excess calories in the form of triglycerides, which eventually may have negative consequences (obesity, ectopic adipose deposits, insulin resistance, inflammation, and eventually impaired insulin secretion). We call this phenotypic or systems flexibility (28). Disease onset occurs when and where one or more of these adaptive processes fail. Importantly, diet and lifestyle play both a negative (caloric excess) and positive role: many nutrients serve specifically to optimize these “flexibility processes” (29). Already in 2002, the Diabetes Prevention Program demonstrated in a large 4-year study that, although metformin and lifestyle both were effective in maintaining fasting plasma glucose, the plasma glucose response to an oral glucose tolerance test (OGTT) (a core aspect of phenotypic flexibility) was more efficiently restored by lifestyle change than medication (13).

Type 2 diabetes, from a systems flexibility mechanistic perspective, thus can be caused by the (partial) failure of many combinations of processes involved in maintaining homeostasis (29). Pancreatic insulin secretion, insulin sensitivity of liver, muscle, and various adipose depots, intestinal permeability, and lipoprotein metabolism are some of the processes that need to maintain their flexibility. Figure 1 presents an overview of all major processes involved in glucose control and type 2 diabetes. It demonstrates how many processes are connected. A comprehensive overview of these processes is presented in Ref. (30).

QUANTIFICATION OF SYSTEMS FLEXIBILITY: STRESS RESPONSE BIOMARKERS

Current diagnostic procedures primarily focus on symptoms of T2D. However, parameters such as glycemia, lipidemia, and blood pressure fail to capture the mechanistic underpinnings of the disease. It is imperative to map out the metabolic anomalies that drive these (plasma) markers in detail, if we wish to truly cure T2D (31).

Due to a wide variety of reasons (genetic, epigenetic, exposure, diet, stress, exercise, etc.), individuals differ in their “wiring” of phenotypic flexibility, will react differently to acute and chronic (metabolic) stressors, and develop a personal trajectory of metabolic–inflammatory health and disease. Appropriate
therapeutic intervention requires identification of the individual “weak spots” of systems flexibility, allowing personalized advice. The weak spot may be impaired triglyceride storage in adipose tissue resulting in a fatty liver for one (32), for another it may be impaired excretion of VLDL particles from the liver due to a shortage of choline, resulting in a fatty liver (33). A third person may accumulate liver fat due to a shortage of carnitine, causing inadequate fatty acid oxidation (34), etc. Each of these processes needs to be mapped out to carefully design a specific (food and lifestyle based) therapy (35). As an example, individuals with a muscle insulin resistance subtype profit specifically from a Mediterranean diet, while those with predominant resistance of the liver profit from a low-fat diet (36).

To better quantify the specific underpinnings of metabolic derangement, i.e., subtyping of phenotypic flexibility, standardized metabolic stress tests are a promising option (31, 37). Multi-biomarker panels are needed to reflect well-defined and accepted health-related processes (Table 1) that can be used as diagnostics of systems flexibility by quantification in response to standardized stress testing. This type of method now allows to quantify the relative contribution of many relevant processes in pancreas, liver, muscle, intestine, adipose tissue, vasculature, and

---

**Figure 1** | Systems view on processes involved in glucose control and type 2 diabetes. The processes (nodes) are colored according to their involvement with organs (see legend). Blue arrows (edges) indicate a positive effect of one process on another, red arrows indicate a negative effect.
TABLE 1 | Type 2 diabetes subgroup (process) dependent diagnosis–intervention strategies.

| T2D subgroups (see Figure 2, based on processes involved) | Diagnosis (i.e., parameters of the biopassport) | Potential interventions |
|-----------------------------------------------------------|-----------------------------------------------|------------------------|
| 1. Pancreatic β-cell function (impaired insulin secretion) | Oral glucose tolerance test (OGTT) or challenge test: disposition index | Fasting-mimicking diet (FMD); β-cell protective nutrients (MUFA, protein, vit. K, Mg, leucine); β-cell protective drugs (TZDs, GLP-1 analogs, DPP4-inhibition) |
| 2. Muscle insulin resistance (decreased glucose uptake) | OGGT or challenge test: muscle IR index, HbA1C, 2-h glucose | Physical activity (resistance training); Mediterranean diet; low-glycemic index diet; low-carb diet; low refined sugar; fiber (arabininoxylan, alpha-cyclodextrin, resistant starch, beta-glucans) |
| 3. Hepatic insulin resistance (decreased glucose uptake, but increased production and release) | OGGT or challenge test: hepatic IR index, fasting glucose | Low (saturated) fat diet; weight loss; very low-caloric diet; intermittent fasting; wholegrain; choline; carnitine; resveratrol; cinnamon extract; metformin |
| 4. Adipocyte insulin resistance and lipotoxicity | Basal adipocyte insulin resistance index, non-esterified fatty acids, visceral and ectopic fat percentage | Intermittent fasting; FMD: α-lipoic acid; polyunsaturated fatty acid/SFA balance; omega-3 FAs; TZDs; acipimox |
| 5. Vasculature | Blood pressure, LDL-cholesterol, HDL-cholesterol, fasting, and post-prandial triglycerides | DASH diet; low-sodium diet; wholegrain; fiber (pectin, β-glucan); beef root (extract); lycopene; Vit. C; Vit. K; cocoa flavonoids; hydroxytyrosol (olive oil); monacolin K; coenzyme Q10; grape seed extract; chitosan/phytosterols; L. reuteri NCIMB 30242; statins; blood pressure lowering medication |
| 6. Chronic low-grade inflammation | CRP; total leukocytes, cytokines | Physical activity; fish oil/n-3 fatty acids; Vit. D; Mg; flavonoids; curcuminoids; salicylates; TNF-α inhibitors |

Currently, six processes involved in T2D are identified, and for each of them a biomarker approach to quantify the process, and an intervention strategy to optimize/restore, is suggested.

kidney in type 2 diabetes, within a single metabolic challenge test (38) based on a multomics assessment of these changes (39–41). The “amplitude” and the “duration” of disturbance (time needed to get back to homeostatic conditions) are taken as readout. It is of critical importance for proper diagnosis to develop such standardized (metabolic) stress tests.

**Toward a “360° Diagnosis”**

Apart from the above-mentioned extension of biomedical diagnosis to “systems flexibility subtyping,” other factors or criteria are important for further subtyping or personalization in lifestyle interventions for type 2 diabetes subjects. Examples are personal motivation, diet or lifestyle preferences, contextual (e.g., environmental, social, or economic circumstances), health literacy, psychological stress level of a person’s daily life. Ideally, all of these factors are taken into account in an integrated personalized treatment and lifestyle change.

Such a “360° diagnosis” provides input into the shared decision of patient and professional on how to act and why. For example, it is well established that psychological comorbidities (depression and anxiety disorders), socioeconomic factors (education, debts, shift work), health literacy, and personality traits (deficits in problem solving or coping skills) can all hamper lifestyle change, self-management, and drug adherence (42) (Table 2). More so, it might be wise for some patients to first tackle mental disorders, debts or unemployment, and then actively work on diet or exercise.

Furthermore, type 2 diabetes follow-up should not only include biological measures of systems flexibility but also an inventory of critical patient characteristics to set the stage for comprehensive, integrated care (42). The Grid Enabled Measures database has cataloged many of these parameters for obesity and diabetes treatment in the behavioral, biological, environmental, and psychosocial areas1 and, depending on goal, type of intervention, selections can be applied.

Future biomarker developments in T2D may include the combination of personal genome, phenotype, and environment (“Exposome–Phenome–Diseasome Associations”) as proposed by Vasan and Benjamín (43), based on the concept of network interactions (“diseasome”) of all relevant information, spanning from genetics to social interactions, already proposed 10 years ago (44).

**THE INTERVENTIONS**

**Only Systems Interventions Will Work**

As explained above, type 2 diabetes is multifactorial and thus requires systems interventions. This implies that all

---

1www.gem-measures.org (accessed October 1, 2017).
underlying causes are quantified and addressed in a personalized and (chrono-)logical order. These causes fall into categories spanning the range of biological, psychological, sociological/environmental, and spiritual domains. Interventions likely fail if one or more of these domains are not properly addressed, or when the interaction between each of these domains is not well understood. It also means to go beyond the treatment of symptoms, but rather to understand the syndemics behind health problems (45). Each type of intervention is addressed in detail below. Some common features that should mark all interventions include

1. The efficacy of a systems approach is based on its individual components and a tailored analysis of the best combination of components (15).
2. Interventions for lifestyle-related diseases need to be based on “self-empowerment.” Most externally imposed interventions are not sustainable. This is the case for the large majority of interventions, with the LookAHEAD study as prime example (46).
3. Interventions always aim to improve flexibility and/or resilience. This holds for both the biology/physiology and psychosocial aspects.

**Dietary Interventions**

**(Chronic) Calorie Restriction**

There is no doubt that caloric restriction and weight loss ameliorate metabolic anomalies in patients with T2D (47, 48). Indeed, loss of 5% of bodyweight or more reduces HbA1c, lipoprotein levels, and blood pressure. Restricting energy intake to 600 kcal/day for 8 weeks normalizes beta-cell function and hepatic insulin sensitivity in obese type 2 diabetics, coinciding with reduction of hepatic and pancreatic fat content (23, 49, 50). These data clearly indicate that type 2 diabetes is a reversible disease, which can be cured by appropriate dietary measures (although the genetic predisposition obviously never disappears). Interestingly, upon publication of the data, many T2D patients reported similar effects of very low calorie intake in their daily life practice, demonstrating that the disease can also be reversed in a non-research self-empowerment setting (51). (Severe) caloric restriction is difficult to sustain, if not plain deleterious in the long run. Thus, the “DiRECT” study was designed as a 4-year demonstrator of the above-mentioned caloric restriction, where the treatment of 149 type 2 diabetes patients consisted of withdrawal of antidiabetic and antihypertensive drugs, total diet replacement (~850 kcal/day formula diet for 3–5 months), stepped food reintroduction (2–8 weeks), and structured support for long-term weight loss maintenance. The first-year results are published and show remission of type 2 diabetes (i.e., HbA1c below 6.5% without medication) in 48% of the subjects, while the control group (standard care) showed 4% remission. Interestingly, the remission was associated with weight loss, with subjects losing more than 15 kg showing 86% remission (52).

**(Intermittent) Fasting**

Fasting, including caloric energy restriction and different intermittent fasting regimes, has been shown effective in weight loss, improving insulin sensitivity, and decreasing cardiovascular risk in both non-diabetic and diabetic subjects (53–56). A study by Halberg et al. in which participants followed an alternate day fasting scheme while maintaining body weight and fat mass, still demonstrated increased insulin-mediated whole body glucose uptake rates, insulin-induced inhibition of adipose tissue lipolysis, and increased plasma adiponectin levels (57). This suggest that the positive effects of intermittent fasting are not solely attributable to weight loss, but are also driven by other mechanisms enhancing metabolic/phenotypic flexibility. The profound metabolic benefits of intermittent and periodic fasting have been well documented in preclinical experiments. For example, alternate day fasting (i.e., complete fasting for 24 h alternated with 24 h periods of ad libitum intake) fully reverses the high insulin and glucose levels of db/db diabetic mice to normal, despite similar overall food intake and stable bodyweight compared to ad libitum fed animals (58). However, fasting every other day is probably even less realistic than chronic calorie restriction and its effects in humans are poorly understood (59). The periodic and prolonged use of the so-called fasting-mimicking diets (FMDs) may offer an effective and safe alternative for the treatment of T2D in humans. FMDs are meal replacement plans, mimicking the endocrine and metabolic effects of fasting while containing modest numbers of calories. The characteristics of these diets that are critical for appropriate copying of the effects of total fasting (despite considerable calorie content) are lack of refined carbohydrate, a very low-protein content and high levels of healthy fats, all from plant-based sources (60). Both animal and human studies suggest that FMDs can be applied as infrequently as once a month for 5 days, requiring approximately 50% reduction in calories to be effective in promoting strong effects on metabolic syndrome risk factors (61, 62). Remarkably, and in keeping with previous reports (58), animal studies indicate that the effects of the periodic FMD on disease risk factors does not require overall calorie restriction, since mice on the FMD consumed the same number of calories per month as mice on the ad libitum diet (61). The molecular mechanisms that underpin the benefits involve the persistent endocrine and metabolic shifts typically induced by fasting: (1) reduction of (bioavailable) insulin growth factor-1, insulin, ectopic fat storage, and endogenous glucose production; (2) increased adipose lipolysis and fat oxidation; and (3) use of glycerol and ketone bodies instead of glucose as preferred carbon sources (59). Notably, recent experimental evidence suggests that periodic use of FMDs can drive beta-cell regeneration to restore insulin production in animal models of type 2 (and type 1) diabetes (24). The potential benefits of intermittent fasting could lie in “flexibility training”; i.e., the frequent switching between metabolic modes, from glucose to free fatty acids and ketone bodies as energy source, i.e., inherent to fasting (59). This finding is in line with the positive impact of intermittent fasting on insulin sensitivity, inflammatory markers, oxidative damage, and stimulation of autophagy (59, 63, 64).

Some studies, however, did show adverse effects of intermittent fasting in healthy, non-obese subjects, including increased levels of free fatty acids and impaired glucose tolerance (65, 66), suggesting that intermittent fasting should only be applied in metabolically inflexible persons.

No studies as yet have been performed that compare effectiveness of an isocaloric intermittent fasting scheme and caloric energy restriction, or healthy diet intervention. Such studies are
required to confirm the ability to “train” metabolic flexibility with intermittent fasting.

Collectively, currently available evidence strongly supports the clinical potential of periodic fasting as an effective and safe alternative to chronic restriction of calories. FMDs may be a feasible mode to implement this therapeutic strategy.

**Macronutrient Composition**

The macronutrient composition of food is relevant for metabolic control as well. As mentioned above, in theory, abolishing the need to store excess glucose by low-carbohydrate (particularly sugar and starch restricted) diets obviates the need for glucose lowering medication, simply because there is no glucose to be stored. Numerous studies have been performed with low or poorly digestible carbohydrate in type 2 diabetics [e.g., Ref. (67–71)]. Follow-up was 1 year in most of them. The data suggest that, in the short term (4 weeks to 6 months), carbohydrate restriction is effective in terms of glucose and weight control. However, in the long run, the effects in terms of bodyweight, glucose control, and lipid profiles of low-carbohydrate diets do not appear to be superior to those of high-carbohydrate diets (72). A meta-analysis of intervention studies (in diabetic and non-diabetic humans) revealed that substitution of carbohydrates with poly-unsaturated fatty acids significantly reduces plasma HbA1c and insulin, while replacing carbohydrate with saturated fat reduces only insulin levels somewhat (73). Besides carbs and fats, effects of dietary protein on diabetes type 2 also received a lot of attention in literature. The acute insulinotropic effects of especially whey protein have been quite well established (74). This effect seems to be mainly driven by an increase in GLP-1, as well as decreased gastric emptying (75, 76). However, increased insulin production is not a beneficial effect if not accompanied by increased insulin sensitivity. Overstimulation of the pancreas and stimulation of gluconeogenesis by high-protein diets may in the long term even result in increased (muscle) insulin resistance (77), if not compensated by increases in lean muscle mass or weight loss (78, 79). It can thus be concluded that manipulating the macronutrient content of the diet without restriction of calories does not cure T2D in the vast majority of patients, although it can improve the diabetic phenotype to a certain extent.

**Micronutrients and Non-Nutrients**

Many micronutrients and non-nutrients were shown to improve glucose control, interacting with a large variety of pathways and processes. Interestingly, almost all processes involved in maintaining systems flexibility (see above) are targets of micronutrients. These are summarized in many dedicated reviews (17, 29, 80, 81). Micronutrients are involved in ectopic lipid disposition [e.g., choline deficiency reduces fatty acid oxidation (82, 83) and hampers VLDL particle synthesis, and thus stimulates fatty liver (84)]. Various nutritional therapies were shown to be efficacious for non-alcoholic fatty liver disease (84). Nutritional anti-inflammatory compounds (e.g., polyphenols, omega-3 fatty acids) contribute to reversing type 2 diabetes, although primarily in combination with other interventions (85), and in a gender-specific manner (86). Insulin secretion is optimized by zinc (87), magnesium (88), and vitamin D (coinciding with its effect on inflammation and glucose control) (89). In theory, a healthy diet should suffice in the needs of these micronutrients. Given the fact that type 2 diabetics usually do not have a track record in healthy eating, targeted prescription of micronutrients and non-nutrients may be required. Diagnosis of the malfunctioning components of systems flexibility in T2D (or any other disease) will allow the design of specific (nutritional) therapies.

**Personalization**

One of the reasons for the lack of consistent, significant effects of the dietary interventions described above probably pertains to the fact that people are not born or raised equal. Moreover, as described in the previous paragraphs, systems diseases require systems diagnosis based on quantifying phenotypic flexibility. This reveals the underlying physiological disease cause(s), embedded in a complex network of metabolic and inflammatory processes. For optimal systems flexibility, each process needs to function optimally. In type 2 diabetes, many organs and processes can contribute to disruption of (glucose) metabolism (90). The degree of insulin sensitivity of the three main organs involved in maintaining glucose homeostasis (muscle, liver, and adipose tissues), and the degree of insulin excretion by the pancreas can be assessed by measuring glucose and insulin at 30-min intervals during an OGTT, together with fasting free fatty acids (16). The severity of insulin resistance can differ between the various organs, and different interventions may have organ-specific effects related to increasing insulin sensitivity (91), as demonstrated by the example of treatment of type 2 diabetic patients with a very low-caloric diet (VLCD) or physical exercise. When insulin resistance primarily affects muscle, physical exercise rapidly restores glucose tolerance (92). In contrast, patients with insulin resistance of the liver respond particularly well to VLCD (23). However, when β-cell capacity is not sufficient, neither VLCD nor physical exercise will fully reverse glucose tolerance (23, 93–95). Similar tissue-specific metabolic effects of distinct interventions were also demonstrated in the CordioPrev cohort, where the Mediterranean diet specifically improved glucose metabolism in T2D patients who predominantly had muscle insulin resistance, while a low-fat diet specifically benefited patients with liver insulin resistance (36). These observations are supported by mechanistic data on metabolic flexibility, demonstrating differential molecular routes for insulin resistance in distinct organs (96). This begs for systems interventions based on diagnosis of decreased flexibility of (tissue-)specific health-related processes. In taking this concept further, toward all aspects of phenotypic flexibility, Table 1 gives an example of how we envision systems diagnosis and related interventions for T2D. Many systems biology based examples of nutrient–flexibility–health relationships and the ways in which they can be personalized have been reviewed (29). In the area of hypertension, an “integrative approach” was proposed, using a multitude of food products and supplements on top of the DASH diet (97). Recently, an international panel recommendations for the prevention and management of metabolic syndrome with lifestyle also showed clear scientific evidence for lifestyle treatments based
on weight loss and increased energy expenditure through physical activity, for a Mediterranean-type diet, with or without energy restriction, as well as for other similar dietary patterns, next to quitting smoking, reducing intake of sugar-sweetened beverages and meat products (17).

**Physical Activity Interventions**

There is strong evidence for the beneficial effects of physical activity on insulin resistance, type 2 diabetes, dyslipidemia, hypertension, and obesity (98, 99). Even a single exercise bout improves blood pressure, glycemia, carbohydrate oxidation during exercise, and fat oxidation after exercise (100). Physical activity programs were shown to be effective in NAFLD treatment (101). Specific physical activity programs achieve specific metabolic health improvements. For example, high-intensity intermittent exercise was shown to specifically reduce liver fat (102). Sixty minutes of walking resulted in a 75% increase of whole body insulin sensitivity (103). On the other hand, just like overeating, lack of physical exercise as such is associated with a number of lifestyle-related diseases (104–106). Physical activity programs can be targeted to specifically reduce ectopic fat and thus become part of a lifestyle program for T2D. A meta-analysis indicated that especially endurance training (aerobic exercise) had an effect on visceral fat and possibly intrahepatic fat in type 2 diabetics (107).

Mechanisms involved are restoration of metabolic flexibility, the oxidative part of insulin resistance, and reducing the reactive oxygen species production. Also, physical activity attenuates inflammation in a positive manner, which contributes to management and reversal of type 2 diabetes (108). Most of these mechanisms involve the mitochondria and are especially valid for the muscle (109), suggesting a specific benefit of physical activity for patients with muscle insulin resistance.

**The Role of Medication in Lifestyle Therapy**

The current pharmaceutical approach to diabetes care is to assist the patient in maintaining glucose, lipid, and blood pressure control. Metformin primarily decreases hepatic glucose production. Thiazolidinediones assist in fatty acid storage in adipose tissue, thereby increasing the use of glucose as energy source and reducing ectopic fat storage. Sulfonylureas stimulate insulin secretion, DPP4 inhibitors prolong the half-life of insulin-stimulating hormones, and exogenous insulin facilitates organ glucose uptake. Medication is prescribed depending on the stage and severity of the disease. Yet, none of these medications addresses the root cause of T2D and will thus not cure the patient.

Plant-based diets almost immediately reduce the need for insulin in “insulin-dependent” type 2 diabetes (110), because absorption of complex carbohydrates from plants just modestly increases plasma glucose levels, which obviates the need for insulin to facilitate glucose storage. Very strict low calorie (600 kcal/day) dieting restores plasma glucose concentrations to normal in T2D patient in 1 week (23). Yet, although such intervention initiate the reversal of type 2 diabetes, the trajectory toward real cure (i.e., restoration of organ insulin sensitivity and beta-cell insulin excretion) will take much more effort and time. Meanwhile, medication may be needed. Therefore, a lifestyle intervention as therapy for T2D will need to be supervised by medical professionals. Notably, patients who choose to adopt lifestyle changes to treat their T2D often need to convince their doctors to adapt their medication. Doctors generally consider medication as required for glucose management (111).

In a fully integrated approach to cure of T2D, lifestyle and medication should (sometimes) be combined. Pharmaceutical strategies should be designed to support optimal reversal of tissue insulin resistance and beta-cell failure, i.e., a combined “precision medicine/precision lifestyle strategy.” As described above, type 2 diabetes essentially needs a systems view, systems diagnosis, and systems therapy to restore insulin sensitivity of all relevant tissues (liver, muscle, and adipose), and reactivation of beta-cell insulin secretory capacity. The extent to which insulin sensitivity and/or action are compromised in each of these tissues may differ between patients. Therefore, the treatment strategy should be tailored to personal disease characteristics. For example, hepatic insulin resistance due to hepatosteatosis in a relatively lean subject may be due to impaired fatty acid uptake by subcutaneous fat or by excessive consumption of refined carbohydrates. Combining a PPAR agonists with restriction of sugar (and alcohol) intake could be a beneficial “food-pharma” couple.

Depending on the disease progression, two other aspects related to medication need to be taken into account. First, not all aspects of systems flexibility may be fully restored, as irreversible damage may have occurred. For example, impaired insulin production can be reversed by reducing pancreatic fat storage and glucose toxicity (112), but beta-cell damage may not be fully reversible. Second, not all comorbidities and pathologies resulting from hyperglycemia are reversible, although the causal drivers (obesity, hypercholesterolemia, hyperglycemia) can be reversed. Indeed, cardiovascular, renal, ocular, and neural complications might need specific medication.

**Sustained Behavior Change**

A lasting change in health requires sustainable lifestyle changes of individuals and active self-management. Behavioral change interventions are designed to affect the actions that individuals take with regard to their health. These interventions can be directed at the individual via psychological determinants of behavior, or target their social or physical environment to create a supportive environment.

First of all, for sustained behavior change, various phases need to be confronted. Initiation of behavior change is by no means a guarantee for continuation. Rothman et al. suggested four phases of behavior change: behavioral initiation, continuation, maintenance, and habit (Table 3) (113). Before the phase of initiation of new behaviors, old habits (like unhealthy eating) are prominent. In the phases of initiation and continuation, the newly adopted behaviors can be in conflict with old patterns, and within this phase the relapse to old habits is likely. If the new behavior becomes the dominant response across context, and people are able to override previous automatic responses, maintenance, and habit become likely. Each phase needs tailored...
Behavior change strategies (113). Whereas the initiation phase is mainly based on outcome expectations and efficacy beliefs, continuation depends on the reward gained from the behavior and self-regulatory skills like planning, sustained self-efficacy, self-regulatory effort, including self-monitoring (114, 115). Maintenance has been linked to factors like self-identity, satisfaction/enjoyment of the new behavior (116). A new habit is achieved when the newly formed behavior has become the automated response.

Behavior change interventions have been effective in creating changes in physical activity and dietary intake (117, 118) and have resulted in changes in HbA1c levels (119), especially for those with a higher baseline HbA1c and for interventions of at least 1 year. Behavioral maintenance of physical activity and dietary behaviors can be achieved when these interventions are adopted in the Netherlands for cardiac patients and could be easily adjusted to type 2 diabetes.

Studies that have effectively supported type 2 diabetes patients have been based on:

- prompt focus on past success (identifying and emphasizing successful behavior change from the individual's past);
- barrier identification/problem-solving (identifying salient barriers to physical activity for the individual and strategies to overcome them);
- use of follow-up prompts (such as reminder postcards or motivational telephone calls);
- provide information on where and when to perform the behavior (individuals are given explicit information on locations, times, and opportunities available locally for changing physical activity behavior);
- prompt review of behavioral goals followed by revisions or adjustments (121);
- maintenance motives (focusing on reward of changing the behavior) (122);
- environmental restructuring (to facilitate the desired behavior) (123).

Lifestyle change is not an effortless or innately pleasurable process for most people. Thus, engaging in healthy behaviors needs to be fulfilling or rewarding—until the long-term benefits of the new healthy lifestyle become manifest and the new lifestyle has become habitual. Reward-based reinforcement is a much-researched learning theory strategy to promote behavior change, which includes vicarious reinforcement (imitating behaviors of others who have experienced rewards due to the behavior) and incentives [which can be (financial) presents]. Incentive-based interventions have been successfully applied to various areas of behavior change, ranging from smoking cessation and physical exercise to counseling attendance and medication adherence (124). Reward-based approaches address the principle that people are prone to succumb to instant gratification, rather than investing for the future. Some people are more prone to instant gratification, and it is often associated with the immediate reward of eating. Meta-analytical evidence shows that providing (financial) incentives is an effective strategy in health behavior change (124). As a consequence, reward-based programs have gained a lot of interest among policymakers and governments. Both the United States and the United Kingdom governments advocate the use of incentives to encourage healthy lifestyle choices and have started large-scale reward programs that target vulnerable populations. In South Africa, health insurer discovery has developed an advanced reward program that collaborates with businesses to form a “lifestyle loyalty” program. Participants earn reward points for all kinds of health activities and behaviors, and the points can be exchanged for goods and discounts at local and national businesses. Active participation in the program showed to increase exercise, healthy food purchases, and decrease healthcare costs. A comparable approach is adopted in the Netherlands for cardiac patients and could be easily adjusted to type 2 diabetes.

Persuasiveness is a key element to promote behavioral maintenance and adherence to interventions (125). Although monetary rewards may function as incentives, other types of persuasive design methods of [eHealth (eHealth)] interventions have been examined as a means to increase engagement with interventions and behavior change. Whereas the behavior-change strategies are mainly targeting primary task support, supporting behavior change, other persuasive design features focus on dialog support, increasing attractiveness of interventions or the reward of behavior change. A particular persuasive strategy is gaming or gamification principles. These so-called serious games are not only meant to entertain but also aim to educate or promote behavior change. Serious games can promote the use and adherence to behavior change interventions. Indeed, a recent meta-analyses examining the role of video games in the promotion of lifestyle changes, suggested that serious gaming is effective, albeit to a limited extend (126, 127). A particular type of gaming has been exergaming or active video games, which are games that require physical activity. These include games, such

| Attaining habits | Individual | Coaching methods |
|------------------|------------|------------------|
| Onboarding       | Identification—who am I | Motivational interviewing and tailoring |
| Initial effort   | I want this | Goal setting |
|                  | I can do this | Action planning |
|                  | I believe the new behavior will help me to realize my goals | Modeling |
|                  | I need to get rid off my old habits | De-conditioning |
| Continue effort  | I know my obstacles and I can overcome them | Problem identification and solving |
|                  | I can maintain the new behavior | Coping planning and self-monitoring, self-evaluation |
| Sustained effort | I enjoy the new behavior and its results | Self-monitoring, self-evaluation |
|                  | I can do this everywhere, anywhere, anytime | Prompt repetition in various contexts |
| Habit            | It is part of who I am | ☺ |

Frontiers in Endocrinology  | www.frontiersin.org  | 9  January 2018  | Volume 8  | Article 381
as dancing games, which generally are done indoor. Exergames seem to be able to contribute to physical activity and bodyweight control, although the effects appear to be limited in uncontrolled settings, and keeping people involved seems a challenge (128, 129). Nevertheless, with the emergence of new types of mobile exergames, for instance, using combined virtual reality and stimulating physical activity at any time and place, exergaming may have potential (130).

Therapeutic alliance is another type of engagement strategy. Therapeutic alliance has been defined as a non-specific feature of treatment, reflecting the extent of collaboration, purposeful action, and emotional connection between a client and therapist. Within the context of interventions guided by healthcare workers, it has been shown that therapeutic alliance increases adherence and effectiveness (131). Also in eHealth interventions, therapeutic alliance has been shown to enhance engagement (132, 133). This certainly is important, as early dropout tends to occur during eHealth interventions.

Lifestyle-based therapy aims to results at reversing and possibly curing type 2 diabetes. Reversal may be achieved within a relatively short period (weeks to months, depending on intensity of the program and severity of the diabetic state). After this “cure phase,” continued support may be helpful lifelong, both focusing on maintaining an optimal lifestyle and on supporting behavior. Figure 2 presents a schematic overview on the various phases, mentioning some of the important components that can be applied during the various phases.

Health Literacy
Health literacy in type 2 diabetes is often but not unambiguously associated with glycemic control and other disease endpoints (134). Since care and cure of type 2 diabetes heavily depend on self-management, and since this is a complex matter involving many aspects of information, awareness, reasoning, and knowledge, health literacy is of high importance. As mentioned above, health literacy should be taken into account when diagnosing a patient.

Health literacy methods are the topic of research and evaluations on their efficacy are in progress. Taken together, multiple aspects and approaches are available and real-life implementation in a tailored, if not personalized manner involving all stakeholders needs to be part of the diabetes care and cure agenda (135).

Structural Interventions for Risk Groups
Besides individual support, structural interventions should be initiated for particular groups of people with T2D that hamper changing their lifestyle due to social–contextual constraints, including neighborhood characteristics, availability of foods, poverty, the local role of primary care, etc. (136). Structural interventions, i.e., interventions aimed to alter the context in which people are living, are likely to promote sustainability and may have additional positive effects on people, besides lifestyle changes and changes in physical health, such as lower experienced loneliness, improved social cohesion, etc. (137). This in particular may be needed for people at risk, e.g., citizens of low socioeconomic gradient, as they are often experiencing a multitude of problems, which need to be targeted by interventions to enable them to effectively change their lifestyles (138). Solutions are sought in community-oriented multidisciplinary primary care interventions in many countries.

eHealth and mHealth in Type 2 Diabetes
Information and communication technologies, i.e., eHealth, can facilitate health care (139). Particularly in the area of eHealth self-management for chronic somatic conditions, guided and embedded interventions have been shown to be as effective as face-to-face treatment but are usually more cost-effective (140). In type 2 diabetes, innovations in eHealth have a demonstrated potential for supporting patients with self-management behaviors, in particular dietary and physical activity behaviors, and may result in better diabetes outcomes such as HbA1c (141). Innovations that can have positive impacts on self-management behaviors include text messages, smartphone apps, and web-based programs (141). Several systematic reviews showed that telemonitoring can improve HbA1c levels (142–144). Video games, virtual and augmented reality, and wearables are also promising, but individuals should be adequately trained in the use of these technologies (141). Moreover, guided eHealth

[Figure 2: Schematic representation of a personal cure and maintenance trajectory. Depending on the personal 360° diagnosis, the duration and intensity of the cure and maintenance phases and the relative contribution of the components may vary.]
interventions are usually more effective than non-guided interventions (140), which urges for “blended care” solutions, so that eHealth is part of a structured care plan.

Thousands of mobile (mHealth) apps for diabetes are available for download in App stores (145). Only a small number of the available apps are evidence based (146). Some systematic reviews and meta-analyses showed that mobile phone interventions lead to improvements in glycemic control and self-management (147, 148). Apps for diabetes self-management typically share a limited number of basic functions, which can be classified into several categories, e.g., self-monitoring, education, support, alerts and reminders, and communication (149). To evaluate the effectiveness of the different functions on glycemic efficacy, Wu et al. developed a taxonomy of apps for diabetes self-management (150). In line with earlier studies, they showed that the use of mobile app-based interventions yields a clinically significant HbA1c reduction among adults with type 2 diabetes. Having a complication prevention module and/or a structured display was associated with a greater HbA1c reduction. Other functions (medication management, generation education, personalized feedback, communication, potential-risk intervention with clinical decision-making) were not associated with greater HbA1c reductions.

eHealth and mHealth can be applied both in the management and prevention of diabetes and thus should be embedded in the continuum of prevention, care, and cure. The American Diabetes Association stated that eHealth technologies, such as Internet-based social networks, distance learning, DVD-based content, and mobile applications may be a useful element of effective lifestyle modification to prevent diabetes (151). The US Center for Disease Control and prevention and the Diabetes Prevention Recognition Program have begun to certify eHealth- and mHealth-based modalities as effective media for diabetes prevention interventions that may be considered together with more traditional face-to-face and coach-drive programs (blended care). Apps for weight loss and diabetes prevention have been validated for their ability to reduce HbA1c in the setting of prediabetes (152). Traditionally, most weight loss apps focus on reducing caloric intake, but for people with (pre)diabetes it is more important to make food choices that induce normal post-meal glycemic responses (153).

mHealth can be greatly improved when ICT technologies are combined with evidence-based behavior change interventions. It has been shown that eHealth interventions that use more behavior change strategies were more likely to effectively change health behavior (physical activity, healthy eating, weight loss) (118, 154). And through, e.g., cultural tailoring (e.g., tailoring to gender, age, religion, ethnic background, or health literacy) acceptance, loyalty, and effectiveness of digital health can be improved (155). Furthermore, computer-tailored interventions have become increasingly common for facilitating improvement in health behaviors. Dynamic tailoring (where the intervention variables are assessed before giving feedback) was shown to be more efficacious than static tailoring (all feedback is based on one baseline assessment) and has long-term effects (156). For all eHealth interventions, guided treatments are usually more effective than non-guided treatments (140).

Combining face-to-face counseling with extended care (via dynamically tailored support) has a potential to increase the effectiveness of T2D management (157). There is a clear need for delivery systems to use team-based models and engage patients in shared decision-making (SDM), where patients and providers together make healthcare decisions that are tailored to the specific characteristics and values of the patient. It has been demonstrated that such an approach leads to patients reporting better understanding of diabetes and showing improved hemoglobin HbA1c values, while healthcare providers reported the SDM aids increased cohesion among team members (including patients) and facilitated patient education and behavioral goal setting (158). In a large pragmatic trial making use of motivational interviewing, SDM, and collaborative goal setting in chronic conditions, a striking difference in mortality rates was found after 2 years of telephone-based health coaching (OR = 0.64; \( p = 0.005 \)), which was achieved with an average of 12.9 calls per patient (159).

The Value of a Timeline of the Health and Behavior Trajectory

Ideally, biomarkers and diagnostics develop into two dimensions. First, from a single process to the complete quantification of health, including flexibility (“systems flexibility biomarker,” described above), and second, along the timeline of an individual’s health trajectory, building the life story of systems flexibility, a personal “biopassport.” Loss of systems flexibility is a process that develops over the timespan of many years. Interventions are most successful in early stages, when full reversal and cure is possible. The storage and availability of biomarker data has been common practice in longitudinal cohorts, but the translations of its results into health care is a tediously slow process. Also, personal health(care) data are usually not available in a structured and understandable manner for the citizen/patient to valorize for his personal health. Since lifestyle-related health is primarily dependent on self-management and self-empowerment, it is vital that the citizen/patient has access to all relevant health data and information (8). If biomarkers of phenotypic flexibility are the key in optimizing metabolic health and in prevention and treatment of metabolic diseases, they need to be measured in regular intervals. At this moment, this is not practical and not affordable, and moreover most healthcare systems neither focus on nor reimburse preventive diagnostics. Therefore, new diagnostic applications need to be developed which are cost-effective, minimally invasive in preferably “do-it-yourself” applications. Developments, both in ICT (personal health portals) and in diagnostics (“gadgets,” dried blood spot diagnostics, etc.) are rapidly disclosing this area. Various sensors (e.g., wearable, on-phone, at home) and other measurement devices (e.g., glucose monitors, weighing scale) have become cheaper and more user friendly. The challenge is to use these techniques in a complementary manner (160). As an example, the “Nutrition Researcher Cohort” (161) started this movement in 2011. However, this cohort encountered major obstacles related to research ethics as it appeared to be virtually impossible to merge personal health data collection
outside the healthcare institutions, both commercial and non-patient centric initiatives have emerged, either from within or support personal healthy living and lifestyle-based therapies.

the personal availability of the timeline of health data will trig-

eralizing this movement (cohort as part of the Precision Medicine Initiative is profes-

tionality. This is rapidly becoming a powerful tool for surveillance (166). These opportunities now move from surveillance to research tools (166), but it may take some time before they become applicable for personal diagnosis due to privacy and ethical constraints. A biopassport is the ideal starting point for the design of lifestyle-based personal health optimization and self-empowerment strategies. The biopassport can be extended with the above described “360° diagnosis.” eHealth applications can be tapped into the biopassport to deliver advice and guidance. Ecologi-

cal Momentary Assessment/Intervention application can be embedded in and will enrich the biopassport (167). Essentially, the personal availability of the timeline of health data will trig-
g a wealth of applications and economic developments that support personal healthy living and lifestyle-based therapies.

Health Data Cooperatives As Ultimate Platform of Health Democracy

Science, business, and society now begin to realize the value of citizen-owned health data (8). Numerous participant or patient centric initiatives have emerged, either from within or outside the healthcare institutions, both commercial and non-profit, and all of them based on Internet and social networking (168, 169). An enormous power is being unlocked in extend-
ing and integrating these data, and this is acknowledged by investments in this area through companies like 23andMe and PatientsLikeMe, and activities of most major “big data companies” (170). Of course, the best entity to valorize citizen-owned health data for any purpose (science, health care, or economy) should be the legal owner, i.e., the citizen itself. The “Health data Cooperative” (171) may be an attractive model for this purpose, as it is the most democratic shared ownership and decision-making legal entity available. This would unlock the value of personal health data for the benefit of personal and public health, facilitate an optimal merge between healthcare quality management and research, and provide the citizen/ consumer/patient with the power to become the center of health care. If indeed the economic value of health data can be invested for the genuine benefit of the citizen/consumer/patient instead of commercial stakeholders, this has the potential to disrupt the current healthcare system into a citizen-centered and self-empowering healthcare system and economy, where services can be implemented that can optimize health, prevent lifestyle-related disease, and cure these using the right tools. Among the right tools should be support of a structured population health management strategy aiming at stratification of the population with T2D according to their risk of various relevant adverse health outcomes. This can be realized with linkage and advanced analysis of (when needed coded and anonymized) routine healthcare data from all domains, result-
ing in a structured approach of individuals who are member of subpopulations sharing defined risks.

Toward Integrated “Companion Systems”

Once the above expose materializes in actionable interventions, the type 2 diabetes patients will be overwhelmed by a wide range of advice and information. Generally speaking, these patients have not shown excellence in adherence to advice nor have they all the skills required to adequately deal with a wide range of advice and information. Thus, many components line up for a new failure in implementation and dropout of patients after initial start. Especially, if we look at mHealth we see the number of mobile phone apps for type 2 diabetes is enormous, being the largest application area in the 100,000+ health Apps available in 2014 (145). It is unlikely that any of these apps covers all areas needed, and it is unlikely that any significant percentage of type 2 diabetics will be able to sensibly maneuver among this overwhelming offer.

We therefore propose a different approach, where a multitude of overlapping personal advice systems applications are replaced by an integrated ecosystem of health services, provided to the end-user in an “on demand” manner based on real-time needs. Health services can span advice on diet, medication compliance, physical activity, behavioral guidance, health and product information, community building, etc. These services should only be presented to the (ex-) type 2 diabetes patient when relevant and needed, in a format and language that is fine-tuned to the user’s socioeconomic-cultural needs, and optimally facilitate liaison with healthcare professionals. Obviously, these services can become very complex and may include artificial intelligence, ecological momentary assessment and interventions, just in time adaptive interventions and similar approaches. Also, a wealth of personal health data can be used as input, spanning from personal health monitoring to medical records. Yet, none of this complexity should be visible to the end-user, but the interaction with this “life companion” should be minimalized to non-intrusive essentials matching the health literacy of the user. Various presentation modes (mobile, desktop, life coaching, or SDM) are possible. Figure 3 presents a schematic overview of the functionalities of a life companion approach. Examples are emerging which combine the layers described above, integrating all aspects of P4-medicine (personalized, predictive, preventive, and participatory) with data- and knowledge drive advice systems in the area of type 2 diabetes (172).

THE ENVIRONMENTAL SUPPORT

Most of the arguments presented above deal with optimizing the biological interventions within a self-empowerment behavioral change setting. Yet, if we agree that a systems solution is the only way forward toward a cure, the other side of the equation also needs to be addressed, i.e., coping with the diabetogenic environ-
m, and ideally changing the diabetogenic environment (Table 4). Behavioral change technologies connected to eHealth
Type 2 diabetes is a systems disease where solutions need to be found in all three systems mentioned to achieve a transition from care to cure. Social system, Physiological system, Healthcare system

T2 diabetes is a “systems disease”
- Obesogenic environment
- Limited engagement with health status
- Social interactions are important for outcome

T2 diabetes initiates when one or more biological processes lose flexibility

Diagnostic of all relevant processes and predispositions
Goal: regain flexibility in all relevant processes, exploiting diet, lifestyle, medication, and genetics where relevant

Optimal coaching, participation, and communication
Integration of medical, social, economical, and mental solutions

Patient empowerment
Implements regional setting
Acceptance by accreditation

Solutions and personal health data valorization are essential in coping with both the biological and environmental pressure to consume calories. Other components of the system entail the environmental support. This includes family, community, and other social structures, primary healthcare centers, other health services, food providers, policies, and regulations. The efficacy of these “population based lifestyle interventions” has been reviewed (173) and evaluated (174), where, six categories of interventions were taken into account, ranging from educational campaigns to taxation. Apart from the efficacy assessment of each of these approaches, a clear statement was made about the need of a combined, “systems” approach (15). The Chicago-based South Side Diabetes Program is a rare example of a systems approach taking into account all these levels in a real-life setting (175, 176). This program demonstrates how a multitude of tools (or “interventions”) can be implemented in, and fine-tuned toward a socio–ethnic–economic setting, involving various levels of society. It also demonstrates the complexity and the hurdles of implementing such neighborhood programs outside and independent of research funding. Essentially, for such programs to become effective and sustainable, they need to be fully incorporated in a profitable economic system.

The Role of the Healthcare System

The healthcare system will need some adaptations to embrace a lifestyle-based cure program for type 2 diabetes, as prototype for many others to follow (Table 4). Healthcare systems vary by country but some generic issues might be addressed. A better education on diet and lifestyle for medical professionals is needed. A financial system which allows for early investments in lifestyle-based cure (diagnosis, coaching) instead of postponing spending until comorbidities emerge would facilitate implementation. Also, the need for “evidence based accreditation” connected to reimbursement by insurance companies might be a relaxed a bit as the type of lifestyle interventions discussed in this article will never have the economic value to justify “pharma-like” studies. As alternative, the “citizen-science” approach discussed above will slowly substitute the randomized controlled trials now promoted.
The Economy of Healthcare: From Disease Focused Products to Health-Oriented Services

A sustainable shift toward healthier lifestyle will not be easy to achieve. In fact, until now, neither scientific experiments nor implementation of lifestyle changing programs have demonstrated their efficacy for sustained type 2 diabetes prevention (177). Yet, in treatment of T2D, this has been demonstrated (13, 14). Clearly, individuals themselves are directly responsible for what they eat, how they exercise, etc. However, a complex interplay between many external agents: regulators, industrial sectors, medical professionals, the media, and social networks influence the choices individuals make (178). Making healthier choices are critical for the future health of our bodies and our societies. The multifactorial character of lifestyle change in relation to obesity has been evaluated, taking all biological, economic, and societal aspects into account (15), indicating that no single change will have any major effect on obesity, and a systems approach or multi-domain approach is essential. This might be achieved on a society level but will need a concerted action of all stakeholders and would imply major shifts in economic values, so is unlikely to happen with consensus of the current stakeholders. For example, in the current food supply chain, unhealthy food is cheap and healthy food is expensive, which does not help in making the right food choices for the majority of the population.

The food and nutrition market faces major challenges. The Western world suffers from too much and relatively cheap food with low-nutrient content but high-caloric density, mostly derived from low-cost ingredients like vegetable fat and sugars. This is a trend rapidly adapted by the developing world (179). Food industry finds difficulties in providing scientific evidence that their products are healthy or have added health value (180), which might create added product value. Two key solutions here are the availability of foods with substantiated health benefits and the facilitation of personal healthy food choices, and acknowledging that food can be used as medicine, i.e., removing the artificial legal barrier to connect therapeutic or medical health claims to foods and nutrients (180, 181). These barriers historically make sense but impede the proper use to food in prevention of chronic disease or as therapy to treat lifestyle-related disease.

An essential part in this process is the individual’s self-empowerment in making healthy choices, by having access to reliable and actionable information to one’s personal health status through access to longitudinal personal health data, as described above. In shaping this new reality, self-empowerment needs to be embedded, in, and possibly even become the driver of a new healthcare economy based on personal data ownership (171). Development of systems diagnosis with preventive and personalized interventions may create and trigger a series of commercial service-based health industry activities in the area of diagnostics, personal food solutions, food–pharma combinations, health advice systems, etc. Food companies may shift their product portfolio from product branding to product–service combinations (personalized products connected to a diagnostic service), food services may be integrated into a health-based personal portfolio, ICT services will emerge based on a personal Biopassport (interpretation of an individual’s health data and relate this to actionable and understandable nutrition and lifestyle advice). Numerous business opportunities can be envisioned in a health economy which focuses on cure instead of care. These include pharma, food, retail, fitness, artificial intelligence, pharmacy, eHealth, diagnostics, coaching services, and workplace health programs. All of this needs to be developed based on evidence-based science a within adequate regulatory–ethical frameworks. In other words, there is some work to be done.

Motivational coaching, both personal and by using ICT means, can be fully developed and implemented if financed in a healthcare system that appreciates the value of prevention and lifestyle therapy for lifestyle-related diseases. The developments in this area are rapid and promising (182, 183).

CONCLUSION AND CALL TO ACTION

In this article, we provide evidence for the reversibility of insulin resistance and the remission of type 2 diabetes, specifically by diet and lifestyle. Complete cure may be achieved if beta-cell function is still appropriate and complications have not yet occurred. We demonstrate that T2D is a “systems disease” with multiple organs and processes involved and consequently deserves to be treated in a personalized manner, if necessary in a “personalized lifestyle-personalized medicine combination.” Compliance to lifestyle change has been a major obstacle for implementation in health care, but the advancements in behavioral change technologies, eHealth, health literacy, and personal health data valorization now may allow for a switch from a research setting to real-life socioeconomic implementation. Enough arguments and instruments are currently available to implement a lifestyle-based therapy for type 2 diabetes and other food-related lifestyle diseases and to extend this to a prevention and optimal health focused health care. Also, we argue that in doing so, an enormous economic gain will be achieved, which is well able to finance a lifestyle-based prevention and optimal health focused health care and economy. Since stakeholders, losses, and profits in this new economy will substantially differ from the current situation, the current healthcare industry will only slowly transit toward this new situation. Creative ways of implementation thus need to be explored. Ultimately, health data cooperatives may become the basis and drivers for this change, but this will take some time to develop into an economic reality. In the meantime, creative new “ecosystems” need to be explored that combine all necessary instruments for specific type 2 diabetes populations to be really effective. The goal would not only be to demonstrate its therapeutic efficacy but also and possibly more important to demonstrate that a new health economy that provides the services (coaching, ITC, foods, diagnostics, medication, all of these personalized and integrated) can become profitable while significantly reducing the net healthcare costs.

Such ecosystems should preferably be regional, facilitating the simultaneous change of all relevant components if the “change system” to interact. This will allow community building,
involvement of local healthcare centers, the local health and lifestyle-related economy, etc. The Chicago based south side diabetics project is a good example (175).

The good message is that many early adopter activities, programs, and movements are already active in this area, covering parts of what is needed. A challenge will be to connect and integrate these into functional and flexible programs that can deliver “tailored systems solutions” depending on the personal and subgroup needs.

The major challenge will be to fund these programs, at least to the point that they become self-sustainable. Here, sustainability does not necessarily imply a profitable service as such, but the identification of new natural funders, i.e., the entities that profit from the new systems. Besides the actual service providers, these can be governments, health insurance, employers, and investors.

In other words, only a temporary funding of a transition phase needs to occur, once the architecture of such ecosystems is in place.

**AUTHOR CONTRIBUTIONS**

All authors have contributed significantly, both related to their own scientific discipline and expertise, and to the overall manuscript. First author coordinated the writing and provided the architecture.

**FUNDING**

All authors have permanent positions with their institutes and thus funded from institutional sources.

---

**REFERENCES**

1. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. *N Engl J Med* (2017) 376(3):254–66. doi:10.1056/NEJMra1514009
2. Arsenault BJ, Després JP. Cardiovascular disease prevention: lifestyle attenuation of genetic risk. *Nat Rev Cardiol* (2017) 14:187–8. doi:10.1038/nrcardi.2017.20
3. Perandini LA, de Sá-Pinto AL, Roschel H, Benatti FB, Lima FR, Bonfá E, et al. Exercise as a therapeutic tool to counteract inflammation and clinical symptoms in autoimmune rheumatic diseases. *Autoimmun Rev* (2012) 12(2):218–24. doi:10.1016/j.autrev.2012.06.007
4. Anand P, Kunnukakara AR, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, et al. Cancer is a preventable disease that requires major lifestyle changes. *Pharm Res* (2008) 25(9):2097–116. doi:10.1007/s11095-008-9661-9
5. WCRS. *Continuous Update Project* (2017). Available from: http://www.wcrf.org/int/research-we-fund/continuous-update-project-cup (Accessed October 1, 2017).
6. Hood L. A personal journey of discovery: developing technology and changing biology. *Annu Rev Anal Chem (Palo Alto Calif)* (2008) 1(1):1–43. doi:10.1146/annurev.anchem.1.031207.113113
7. Sagner M, McNeil A, Psika P, Auffray C, Price ND, Hood L, et al. The P4 health spectrum – a predictive, preventive, personalized and participatory continuum for promoting healthspan. *Prog Cardiovasc Dis* (2017) 59(5):506–21. doi:10.1016/j.procard.2016.08.002
8. Kish LJ, Topol EJ. Unpatients – why patients should own their medical data. *Nat Biotechnol* (2015) 33(9):921–4. doi:10.1038/nbt.3340
9. Bragazzi NL. From P0 to P6 medicine, a model of highly participatory, patient-centered care. *Patient Prefer Adherence* (2016) 10:1–9. doi:10.1111/pa.12679
10. Price ND, Magis AT, Earls JC, Glusman G, Levy R, Lausted C, et al. A wellness intervention in patients with type 2 diabetes: a meta-analysis. *Metabolism* (2015) 64(2):338–47. doi:10.1016/j.metabol.2014.10.018
11. Kish LJ, Topol EJ. Unpatients – why patients should own their medical data. *Nat Biotechnol* (2015) 33(9):921–4. doi:10.1038/nbt.3340
12. Bloom DE, Cafero ET, Jané-Llopis E, Bragazzi NL. From P0 to P6 medicine, a model of highly participatory, patient-centered care. *Patient Prefer Adherence* (2016) 10:1–9. doi:10.1111/pa.12679
13. Price ND, Magis AT, Earls JC, Glusman G, Levy R, Lausted C, et al. A wellness intervention in patients with type 2 diabetes: a meta-analysis. *Metabolism* (2015) 64(2):338–47. doi:10.1016/j.metabol.2014.10.018
van Ommen B, van der Greef J, Hankemeier T, McBurney RN. Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials? Pharmacogenomics (2006) 7(7):1087–94. doi:10.2217/14622416.7.7.1087

Liss KHH, Finck BN. PPARs and nonalcoholic fatty liver disease. Biochimie (2016) 136:65–74. doi:10.1016/j.bioch.2016.11.009

van Ommen B, van der Greef J, Ordovas JM, Daniel H. Phenotypic flexibility and the case for human and bacterial genes. Adv Nutr (2016) 7(1):5–13. doi:10.3945/an.114.007955

Malaguarnera M, Gargante MP, Russo C, Antic T, Vacante M, Malaguarnera M, et al. ω-3 fatty acid supplementation in a new tool in treatment of nonalcoholic steatohepatitis – a randomized and controlled clinical trial. Am J Gastroenterol (2010) 105(6):1338–45. doi:10.1038/ajg.2009.719

van Ommen B, Keijzer J, Heil SG, Kaput JJ. Challenging homeostasis to define biomarkers for nutrition related health. Mol Nutr Food Res (2009) 53(7):795–804. doi:10.1002/mnfr.200800390

Wopereis S, Stroeve JHM, Stafleu A, Bakker GCM, Brouwer IA, van Erk MJ, et al. Multi-parameter comparison of a standardized mixed meal tolerance test in healthy and type 2 diabetic subjects: the PhenFlex challenge. Genes Nutr (2015) 12(1):21. doi:10.1007/s12263-015-0570-6

Pelissi L, Erik MJ, Ommen B, Bakker GCM, Hendriks HJF, Cnubben NHP, et al. Plasma metabolomics and proteomics profiling after a postprandial challenge reveal subtle diet effects on human metabolic status. Metabolomics (2011) 7(2):347–59. doi:10.1007/s11306-011-0320-5

Van den Broek TJ, Kremers JPA, Marcondes Rezende M, Hoevenaars FPM, de Wit NJ, Afman LA, Mensink M, Müller M. Phenotyping the effect of diet on non-alcoholic fatty liver disease. J Hepatol (2012) 57(6):1370–3. doi:10.1016/j.jhep.2012.07.003

Blanco-Rojo R, Alcala-Diaz JF, Wopereis S, Perez-Martinez P, Quintana-Navarro GM, Marin C, et al. The insulin resistance phenotype (muscle or liver) interacts with the type of diet to determine changes in disposition index after 2 years of intervention: the CORDIOPREV-DIAB randomised clinical trial. Diabetologia (2015) 59(1):67–76. doi:10.1007/s00125-015-3776-4

van Ommen B, Keijzer J, Heil SG, Kaput JJ. Challenging homeostasis to define biomarkers for nutrition related health. Mol Nutr Food Res (2009) 53(7):795–804. doi:10.1002/mnfr.200800390

Wopereis S, Stroeve JHM, Stafleu A, Bakker GCM, Brouwer IA, van Erk MJ, et al. Multi-parameter comparison of a standardized mixed meal tolerance test in healthy and type 2 diabetic subjects: the PhenFlex challenge. Genes Nutr (2015) 12(1):21. doi:10.1007/s12263-015-0570-6
88. Barbosa SG, Folli F, Vitamin D, sub-inflammation and insulin resistance. A window on a potential role for the interaction between bone and glucose metabolism. *Rev Endocr Metab Disord* (2017) 18(2):243–58. doi:10.1007/s11192-017-9423-2

89. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. *Diabetologia* (2010) 53(7):1270–87. doi:10.1007/s00125-010-1684-1

90. Abdul-Ghani MA. Contributions of cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. *Diabetes Care* (2006) 29(5):1310–9. doi:10.2337/diabetes.2014.154

91. A mixed report on the effect of physical exercise in diabetes. *Int J Endocrinol* (2012) 2012:983814. doi:10.1155/2012/983814

92. Dela F, Von Linstow ME, Mikines KJ, Galbo H. Physical training may enhance beta-cell function in type 1 diabetes. *Am J Physiol Endocrinol Metab* (2004) 287(5):E1024–31. doi:10.1152/ajpendo.00056.2004

93. Goodpaster BH, Sparks LM. Metabolic flexibility in health and disease. *Cell Metab* (2017) 25(5):1027–36. doi:10.1016/j.cmet.2017.04.015

94. Houston M. The role of nutraceutical supplements in the treatment of hypertension. *J Clin Hypertens* (2012) 14(12):31–2. doi:10.1111/j.1751-7176.2011.0176a.x

95. Pedersen BK, Saltin B. Evidence for prescribing exercise as therapy in chronic disease. *Scand J Med Sci Sports* (2006) 16(Suppl 1):3–63. doi:10.1111/j.1600-0838.2006.00520.x

96. Pedersen BK, Saltin B. Exercise as medicine – evidence for prescribing exercise as therapy in 26 different chronic diseases. *Scand J Med Sci Sports* (2015) 25(1):7–22. doi:10.1111/smss.12581

97. Asano RY, Saleh MM, Browne RA, Moraes JF, Coelho Junior HJ, Moraes MR, et al. Acute effects of physical exercise in type 2 diabetes: a review. *World J Diabetes* (2014) 5(5):659–65. doi:10.4236/wjd.2015.65659

98. Oldani G, Delaune V, Morel P, Toso C. Exercise-based interventions for nonalcoholic fatty liver disease: a meta-analysis and meta-regression. *Clin Gastroenterol Hepatol* (2016) 14(10):1398–411. doi:10.1016/j.cgh.2016.04.036

99. Cassidy S, Thoma C, Hallsworth K, Parikh J, Hollingsworth KG, Taylor R, et al. High intensity intermittent exercise improves cardiac structure and function and reduces liver fat in patients with type 2 diabetes: a randomised controlled trial. *Diabetologia* (2016) 59(1):56–66. doi:10.1007/s00125-015-3741-2

100. Schiavon M, Hinsshaw L, Malld M, Dalla Man C, Sparacino G, Johnson M, et al. Postprandial glucose fluxes and insulin sensitivity during exercise: a study in healthy individuals. *Am J Physiol Endocrinol Metab* (2013) 305(4):E557–66. doi:10.1152/ajpendo.00182.2013

101. Pedersen BK. The dissecase of physical inactivity – and the role of myokinones in muscle-fat cross talk. *J Physiol* (2009) 587(23):5559–68. doi:10.1113/jphysiol.2009.179515

102. Fletcher E, Leech R, McNaughton SA, Dunstan DW, Lacy KE, Salmon J. Is the relationship between sedentary behaviour and cardiometabolic health in adolescents independent of dietary intake? A systematic review. *Obes Rev* (2015) 16(9):795–805. doi:10.1111/obr.12302

103. Solomon TPI, Thyfault JP. Type 2 diabetes sits in a chair. *Diabetes Obes Metab* (2013) 15(11):987–92. doi:10.1111/dom.12165

104.拿到 3(1):195–210. doi:10.1016/j.ajdbet.2016.12.006
van Ommen et al. From Diabetes Care to Diabetes Cure

108. Pedersen BK. Anti-inflammatory effects of exercise: role in diabetes and cardiovascular disease. *Eur J Clin Invest* (2017) 42:105–17. doi:10.1111/ eji.13667

109. Hesseling MKC, Schrauw-Hinderling V, Schrauw P. Skeletal muscle mitochondria as a target to prevent or treat type 2 diabetes mellitus. *Nat Rev Endocrinol* (2016) 12(11):633–45. doi:10.1038/nrendo.2016.104

110. Anderson JW, Ward K. High-carbohydrate, high-fiber diets for insulin-treated men with diabetes mellitus. *Am J Clin Nutr* (1979) 32:2312–21.

111. Reusch JEB, Manson JE. Management of type 2 diabetes in 2017. *JAMA* (2017) 317(10):1015. doi:10.1001/jama.2017.0241

112. Wang Z, York NW, Nichols CG, Remedi MS. Pancreatic beta-cell dedifferentiation in diabetes and redifferentiation following insulin therapy. *Cell Metab* (2014) 19(3):872–82. doi:10.1016/j.cmet.2014.03.010

113. Rothman AJ, Baldwin AS, Hertel AW. Self-regulation and behavior change: disentangling behavioral initiation and behavioral maintenance. In: Vohs KD, Baumeister RF, editors. *Handbook of Self-Regulation*. London: The Guilford Press (2004), p. 130–50.

114. Janssen V, De Gucht V, Dusseldorf E, Maes S. Lifestyle modification programmes for patients with coronary heart disease: a systematic review and meta-analysis of randomized controlled trials. *Eur J Prev Cardiol* (2013) 20(4):620–40. doi:10.1177/1351278412468284

115. Sniehotta FF, Scholz U, Schwarzer R, Fuhrmann B, Kiusus U, Völler H. Long-term effects of two psychological interventions on physical exercise and self-regulation following coronary rehabilitation. *Int J Behav Med* (2005) 12(4):244–55. doi:10.1007/s10464-005-9007-4

116. Ryan RM, Deci EL. Self-determination theory and the facilitation of behavior change following physical activity and dietary interventions: concepts, challenges and opportunities for research. *J Psychol* (2014) 148(5):557–69. doi:10.1080/00223935.2013.838893

117. Michie S, Wood CE, Johnston M, Abraham C, Francis JJ, Hardeman W. Behaviour change techniques: the development and evaluation of a taxonomic method for reporting and describing behaviour change interventions (a suite of five studies involving consensus methods, randomised controlled trials and analysis of qualitative data). *Health Technol Assess (Rockv)* (2015) 19(99):1–167. doi:10.3310/hta19990

118. Dusseldorf E, van Genugten L, van Buuren S, Verheijden MW, van Empelen P. Combinations of techniques that effectively change health behavior: evidence from meta-CART analysis. *Health Psychol* (2014) 33(12):1530–40. doi:10.1093/hepcom/deu001

119. Ontario Health Department. Community-based care for the management of type 2 diabetes: an evidence-based analysis. *Ont Health Technol Assess Ser* (2009) 9:1–40.

120. Fjeldsoe B, Neuhaus M, Winkler E, Eakin E. Systematic review of maintenance of behavior change following physical activity and dietary interventions. *Health Psychol* (2011) 30(9):109–119. doi:10.1093/hyp/2011.1015

121. Avery L, Flynn D, Dombrowski SU, van Wersch A, Sniehotta FF, Scholz U, Schwarzer R, Fuhrmann B, Kiwus U, Völler H. Successful behavioural strategies to increase physical activity and exercise adherence in type 2 diabetes mellitus — study protocol for a randomized controlled trial. *Trials* (2017) 18(1):103. doi:10.1186/s13636-017-1853-3

122. van Beugen S, Ferwerda M, Spillekom-van Kouil S, Smit JV, Zeeuween-Franssen MEJ, Kroft EBM, et al. Tailored therapist-guided Internet-based cognitive behavioral treatment for psoriasis: a randomized controlled trial. *Pyschther Psychosom* (2016) 85(5):297–307. doi:10.1159/000447267

123. Bailey SC, Brega AG, Cruthfield TM, Els T, Herr K, Kaphingst K, et al. Update on health literacy and diabetes. *Diabetes Educ* (2014) 40(5):581–604. doi:10.1177/0145721714540220

124. Watts SA, Stevenson C, Adams M. Improving health literacy in patients with diabetes. *Nursing (Lond)* (2017) 47(1):24–31. doi:10.1097/01.NURSE.0000510739.60928.a9

125. Mendenhall E, Kohrt BA, Norris SA, Ndeite D, Prabhakaran D. Non-communicable disease syndromes: poverty, depression, and diabetes among low-income populations. *Lancet* (2017) 389(10072):951–63. doi:10.1016/S0140-6736(17)30402-6

126. Blankenship KM, Friedman SR, Dwoorkin S, Mantell JE. Structural interventions: concepts, challenges and opportunities for research. *J Urban Health* (2006) 83(1):59–72. doi:10.1177/0022878905284007

127. Liburd LC, Jack L, Williams S, Tucker P. Intervening on the social determinants of cardiovascular disease and diabetes. *Am J Prev Med* (2005) 29(5):24–31. doi:10.1016/j.amepre.2005.07.013

128. van Gemert-Pijnen JE, Nijland N, van Limburg M, Ossebaard HC, Kelders SM, Eysenbach G, et al. A holistic framework to improve the uptake and impact of eHealth technologies. *J Med Internet Res* (2011) 13(4):e111. doi:10.2196/jmir.1672

129. van Beugen S, Ferwerda M, Hoeve D, Rovers MM, Spillekom-van Kouil S, van Middendorp H, et al. Internet-based cognitive behavioral therapy for patients with chronic somatic conditions: a meta-analytic review. *J Med Internet Res* (2014) 16(3):e88. doi:10.2196/jmir.2777

130. Rollo ME, Aguilar EJ, Williams RL, Wynne K, Kriss M, Callister R, et al. eHealth technologies to support nutrition and physical activity behaviors in diabetes. *Diabetes Metab Syndr Obes* (2016) 9:381–90. doi:10.2147/DMSO.S95247

131. Lieber BA, Taylor B, Appelboom G, Prasad K, Bruce S, Yang A, et al. Meta-analysis of telemonitoring to improve HbA1c levels: promise for stroke survivors. *J Clin Neurosci* (2015) 22(5):807–11. doi:10.1016/j.jocn.2014.11.009

132. Mush acab H, Kornohan WG, Wallace J, Martin S. Web-based remote monitoring systems for self-managing type 2 diabetes: a systematic review. *Diabetes Technol Ther* (2015) 17(7):498–509. doi:10.1089/dia.2014.0296

133. Balshir RL, Shannon GW, Smith BR, Woodward MA. The empirical evidence for the telemedicine intervention in diabetes management. *Telemed J E Health* (2015) 21(5):321–54. doi:10.1089/tmj.2015.0029

134. Mood H, Wilson R, Corsica J, Bradley L, Chirinos D, Vivo A. What do we know about mobile applications for diabetes self-management?
A review of reviews. J Behav Med (2016) 39(6):981–94. doi:10.1007/s10865-016-9765-3

Whitehead L, Seaton P. The effectiveness of self-management mobile phone and tablet apps in long-term condition management: a systematic review. J Med Internet Res (2016) 18(5):e97. doi:10.2196/jmir.4883

Campbell R, Ash J. An evaluation of five bedside information products using a user-centered, task-oriented approach. J Med Libr Assoc (2006) 94(4):435–41. e206–e207.

Wishart DS, Knox C, Guo AC, Eisner E, Young N, Gautam B, et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res (2009) 37(Suppl 1):D603–10. doi:10.1093/nar/gkn810

Chomutare T, Fernandez-Luque L, Årsand E, Hartvigsen G. Features of mobile diabetes applications: review of the literature and analysis of current applications compared against evidence-based guidelines. J Med Internet Res (2011) 13(3):e65. doi:10.2196/jmir.1874

Wu Y, Yao X, Vespasiani G, Nicolucci A, Dong Y, Kwong J, et al. Mobile app-based interventions to support diabetes self-management: a systematic review of randomized controlled trials to identify functions associated with glycemic efficacy. JMIR Mhealth Uhealth (2017) 5(3):e35. doi:10.2196/mhealth.6522

American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care (2016) 39(Suppl 1):S13–22. doi:10.2337/dc16-5005

Sepah SC, Jiang L, Peters AL. Long-term outcomes of a web-based diabetes prevention program: 2-year results of a single-arm longitudinal study. J Med Internet Res (2015) 17(4):e92. doi:10.2196/jmir.4052

Gallwitz B. Implications of postprandial glucose and weight control in people with type 2 diabetes: understanding and implementing the international diabetes federation guidelines. Diabetes Care (2009) 32(Suppl_2):S322–5. doi:10.2337/dc09-9331

Webb TL, Sniehotta FF, Michie S. Using theories of behaviour change to inform interventions for addictive behaviours. Addiction (2010) 105(11):1879–92. doi:10.1111/j.1360-0443.2010.03028.x

Kreuter MW, Lukwago SN, Bucholtz DC, Clark EM, Sanders-Thompson V. Achieving cultural appropriateness in health promotion programs: targeted and tailored approaches. Health Educ Behav (2003) 30(2):133–46. doi:10.1177/1090198102251021

Krebs P, Prochaska JO, Rossi JS. A meta-analysis of computer-tailored interventions for health behavior change. Prev Med (2010) 51(3–4):214–21. doi:10.1016/j.ypmed.2010.06.004

Bob B, Lemmens LJHM, Jansen A, Nederkoorn C, Kerkhofs V, Spanakis G, et al. An ecological momentary intervention for weight loss and healthy eating via smartphone and Internet: study protocol for a randomised controlled trial. Trials (2016) 17(1):154. doi:10.1186/s13063-016-1280-x

Griffith M, Siminerio L, Payne T, Krall J. A shared decision-making approach to telemedicine: engaging rural patients in glycemic management. J Clin Med (2016) 5(1):103. doi:10.3390/jcm5110103

Harter M, Dirmayer J, Dwinger S, Kriston L, Siegmund-Schultze E, et al. Effectiveness of telephone-based health coaching for patients with chronic conditions: a randomised controlled trial. PLoS One (2016) 11(9):e0161269. doi:10.1371/journal.pone.0161269

Mohr DC, Cheung K, Schueler SM, Brown CH, Duan N. Continuous evaluation of evolving behavioral intervention technologies. Am J Prev Med (2013) 45(5):517–23. doi:10.1016/j.amepre.2013.06.006

van Ommen B. The nutrition researcher cohort: toward a new generation of nutrition research and health optimization. Genes Nutr (2013) 8(4):343–4. doi:10.1007/s12263-013-0348-4

Vayena E, Tasioulas J. The ethics of participant-led biomedical research. Nat Biotechnol (2013) 31(9):786–7. doi:10.1038/nbt.2692

Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med (2015) 372(9):793–5. doi:10.1056/NEJMmp1500523

Kohn MS, Sun J, Knoops S, Shabo A, Carmeli B, Sow D, et al. IBM's health analytics and clinical decision support. Yearb Med Inform (2014) 9(1):154–62. doi:10.15255/TYF-2014-0002

Tkachenko N, Chotvijit S, Gupta N, Bradley E, Gilks C, Guo W, et al. Google trends can improve surveillance of a Ref type 2 diabetes. Sci Rep (2017) 7(1):4993. doi:10.1038/s41598-017-05991-9

Ayers JW, Althouse BM, Dredze M. Could behavioral medicine lead the web data revolution? JAMA (2014) 311(14):1399. doi:10.1001/jama.2014.1505

Burke LE, Shiffman S, Music E, Styn MA, Kriska A, Smailagic A, et al. Ecological momentary assessment in behavioral research: addressing technological and human participant challenges. J Med Internet Res (2017) 19(3):e77. doi:10.2196/jmir.7138

Kaye J, Curren L, Anderson N, Edwards K, Fullerton SM, Kanellopoulou N, et al. From patients to partners: participant-centric initiatives in biomedical research. Nat Rev Genet (2012) 13:371–6. doi:10.1038/nrg3218

DeFrancesco L. To share is human. Nat Biotechnol (2015) 33(8):796–800. doi:10.1038/nbt.3309

World Economic Forum. Unlocking the Value of Personal Data: From Collection to Usage. (2013). Available from: https://www.weforum.org/reports/unlocking-value-personal-data-collection-usage

Hafen E, Kossmann D, Brand A. Health data cooperatives – citizen empowerment. Methods Inf Med (2014) 53(2):1–5. doi:10.3341/ME13-02-0051

Bresó A, Sáez C, Vicente J, Larrinaga F, Robles M, García-Gómez JM. Knowledge-based personal health system to empower outpatients of diabetes mellitus by means of P4 medicine. Methods Mol Biol (2015) 1246:237–57. doi:10.1007/978-1-4939-1985-7_15

Mozaffarian D, Afshin A, Benowitz NL, Bittner V, Daniels SR, Franch HA, et al. Population approaches to improve diet, physical activity, and smoking habits: a scientific statement from the American Heart Association. Circulation (2012) 126(12):1514–63. doi:10.1161/CIR.0b013e318260a20b

Mozaffarian D. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity. Circulation (2016) 133(2):187–225. doi:10.1161/CIRCULATIONAHA.115.018855

Peek ME, Ferguson MJ, Roberson TP, Chin MH. Putting theory into practice: a case study of diabetes-related behavioral change interventions on Chicago’s south side. Health Promot Pract (2014) 15(2 Suppl):405–405. doi:10.1177/1524839914552292

Goddu AP, Roberson TS, Raffel KE, Chin MH, Peek ME. Food Rx: a community-university partnership to prescribe healthy eating on the South Side of Chicago. J Prev Interv Community (2015) 43(2):148–62. doi:10.1080/10548739.2015.1072620

Mozaffarian D, Ludvig DS. Dietary guidelines in the 21st century – a time for food. JAMA (2010) 304(6):681–2. doi:10.1001/jama.2010.1116

Debuschs X. Is adherence a relevant issue in the self-management education of diabetes? A mixed narrative review. Diabetes Metab Syndr Obes (2014) 7:357–67. doi:10.2147/DMSO.S36369

Kousoulis AA, Patelaou E, Shea S, Foss C, Ruud Knutsen IA, Todorova E, et al. Diabetes self-management arrangements in Europe: a realist review to facilitate a project implemented in six countries. BMC Health Serv Res (2014) 14(1):453. doi:10.1186/1472-6963-14-453

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 van Ommen, Woerpeis, van Empelen, van Keulen, Otten, Kasteleyen, Molenma, de Hoogh, Chavannes, Nuans, Evers and Pijl. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.